The Keynote-001 NSCLC expansion cohorts demonstrated that PD-L1’s expression in at least 50% of tumor cells correlated with the improved efficacy of pembrolizumab as a monotherapy in treatment-naïve and previously treated advanced NSCLC [13]. The gene discussed is CD274; the disease is neoplasm.